Telmisartan (Micardis, Boehringer Ingelheim), a nonpeptide AT-II-receptor antagonist, gained FDA approval for use in the treatment of hypertension in 1998. After oral administration, peak ...
Zeit Aktuelle Nachrichten 17.01. Boehringer drug for brain fog in schizophrenia fails trial 16.01. Boehringer's phase 3 schizophrenia program misses primary goal 16.01. Boehringer Ingelheim ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback